MedTrace Logo

The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

NCT00421278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-01-22

No results posted yet for this study

Summary

A study to test the effects of study drug (MK 0633) on patients with Atherosclerotic disease

Conditions

Interventions

DRUG

MK0633

Single dose MK0633 100mg po in the fed state administered during a 4-wk study.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2006-12-31
Completion
2007-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00421278 on ClinicalTrials.gov